RBD-IgG levels correlate with protection in Residents Facing SARS-CoV-2 B.1.1.7 Outbreaks
H. Blain*, E. Tuaillon*, L. Gamon, A. Pisoni, S. Miot, V. Delpui, N. Si-Mohamed, C. Niel, Y. Rolland, B. Montes, S. Groc, S. Rafasse, A.M. Dupuy, N. Gros, D. Muriaux, M.C. Picot, J. Bousquet
* Both authors contributed equally to the manuscript
Authors’ full names, academic degrees, and affiliations: Hubert Blain, MD, PhD,1 Edouard Tuaillon MD, PhD,2Lucie Gamon,3 Amandine Pisoni PhD,2Stéphanie Miot MD, PhD,1 Valentin Delpui,1 Nejm Si-Mohamed, 1 Clémence Niel,2 Yves Rolland MD, PhD,4 Brigitte Montes PharmD, PhD2, Soraya Groc2, Sophia Rafasse,5 Anne-Marie Dupuy MD, PhD,6 Nathalie Gros PhD, 5 Delphine Muriaux PhD,5 Marie-Christine Picot MD, PhD,3 Jean Bousquet MD, PhD7
  1. Department of Internal Medicine and Geriatrics, MUSE University, Montpellier, France.
  2. Laboratory of Virology, INSERM U 1058/EFS, University hospital, Montpellier, France.
  3. Clinical research and epidemiology unit, University hospital, Montpellier, France.
  4. Gérontopôle de Toulouse, INSERM 1027; Toulouse, France.
  5. CEMIPAI, University of Montpellier, UAR3725 CNRS, Montpellier, France, and Institute of Research in Infectiology of Montpellier (IRIM), University of Montpellier, UMR9004 CNRS, Montpellier, France.
  6. Biochemistry and hormonology laboratory, University hospital, Montpellier, France
  7. Department of Dermatology and Allergy, Universitätsmedizin, Berlin, Germany and University hospital, Montpellier, France.
Running head: Antibodies and BNT162b2 Effectiveness